ZOLL Respicardia, Inc.
$718.3K 1,630 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Scilex Pharmaceuticals Inc.
Scilex Pharmaceuticals Inc. reported $715,661.88 across General Payments, Research, and Ownership to 19,348 physicians and teaching hospitals across 19,350 transactions.
- $715.7K Above-median payer
- All-tracks total
- 19,350 Top 10% volume
- Transactions
- 19,348 Top 10% reach
- Recipients
- +$168.6K
- General Payments vs PY2023
Scilex Pharmaceuticals Inc. reported $715,661.88 across all CMS Open Payments tracks (General + Research + Ownership) to 19,348 physicians and teaching hospitals in Program Year 2024 - ranking #689 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $677,564.88, averaging $36.99 per recipient.
How Scilex Pharmaceuticals Inc.'s $715.7K all-tracks total breaks down
Scilex Pharmaceuticals Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
74/100
Total payments
F
17/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer scilex-pharmaceuticals-inc Scilex Pharmaceuticals Inc.
$715.7K · #689/1,925 · 0.0% industry · PY2024
- TOT $715.7K
- RANK #689
- SHARE 0.0%
- TXN 19,350
- RCP 19,348
- CAT 6
- GEN $677.6K
- ΔGEN +$168.6K
- TOP1 14.7%
- PY 2024
Volume peers
Nearest volume peer: ZOLL Respicardia, Inc. ($718.3K)
Scilex Pharmaceuticals Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Scilex Pharmaceuticals Inc.'s CMS-reported General Payments increased by $168.6K (+33.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SCILEX PHARMACEUTICALS INC.PY2023: SCILEX PHARMACEUTICALS INC.PY2024: SCILEX PHARMACEUTICALS INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $508,967.56
- PY2024
- $677,564.88
What the Data Shows for Scilex Pharmaceuticals Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Scilex Pharmaceuticals Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Food and Beverage" leads the 6-category general-payment breakdown below at $364.3K (53.8% of General Payments, 19,177 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Scilex Pharmaceuticals Inc. made 6 types of general payments. "Food and Beverage" is the largest category at $364.3K, 53.8% of General Payments.
Scilex Pharmaceuticals Inc. reports 6 general-payment categories - the top three are Food and Beverage (53.8%), Consulting Fee (19.8%), and Compensation for Services Other Than Consulting (16.4%). The remaining 3 categories make up 10.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Scilex Pharmaceuticals Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $364.3K | 19,177 | 53.8% |
| Consulting Fee | $133.9K | 20 | 19.8% |
| Compensation for Services Other Than Consulting | $110.8K | 109 | 16.4% |
| Honoraria | $65.7K | 29 | 9.7% |
| Travel and Lodging | $2.4K | 7 | 0.4% |
| Education | $452.84 | 6 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $175,848.73 (26.0%) of $677,564.88 in this company's General Payments records across 6,478 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Scilex Pharmaceuticals Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Srinivas R Nalamachu
$99,612.86 across 20 reported transactions
- 2
Caitlin E Innerfield
$25,865.20 across 61 reported transactions
- 3
Zachary Mccormick
$17,775.00 across 2 reported transactions
- 4
Joseph Pergolizzi Jr
$17,018.10 across 18 reported transactions
- 5
Stuart Tepper
$15,577.57 across 14 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Scilex Pharmaceuticals Inc. ranks #689 of 1,925 by total payments (top 36% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,487 of 1,838 by HHI (bottom 19% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Oak Med, Inc. : $9.5K total payments, HHI 275
- Ortho Dermatologics, a division of Bausch Health US, LLC : $999.3K total payments, HHI 275
- Nalu Medical, Inc. : $823.0K total payments, HHI 275
- Urgo Medical North America, LLC : $258.8K total payments, HHI 274
- Nobelpharma America, LLC : $21.7K total payments, HHI 272
- Legend Biotech USA Inc. : $189.2K total payments, HHI 272
- Scilex Pharmaceuticals Inc. (this company) : $677.6K total payments, HHI 272
- Applied Medical Resources Corporation : $1.8M total payments, HHI 271
- Enduromed, Llc : $26.2K total payments, HHI 271
- Essential Dental Systems Incorporated : $2.7K total payments, HHI 269
- Shape Memory Medical Inc. : $25.2K total payments, HHI 268
- La Jolla Pharmaceutical Company : $486.9K total payments, HHI 268
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Scilex Pharmaceuticals Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Scilex Pharmaceuticals Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Scilex Pharmaceuticals Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Carl Zeiss Meditec USA, Inc.
$719.3K 2,435 recipients
Compare payment profiles
Kuros Biosciences USA, Inc
$711.3K 1,447 recipients
Compare payment profiles
Napo Pharmaceuticals Inc
$704.8K 1,430 recipients
Compare payment profiles
SurGenTec
$704.8K 249 recipients
Compare payment profiles
Calvary Spine, LLC
$703.2K 0 recipients
Compare payment profiles
Put this to use
Scilex Pharmaceuticals Inc. ranks #689 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Scilex Pharmaceuticals Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.